Ana Abad-Torrent
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ana Abad-Torrent has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Pablo Martinez-Vazquez
Functional Imaging Laboratory, German Primate Center (DPZ)
2 shared publications - Aina Gomila
Department of Infectious Diseases Hospital Universitari Parc Taulí Sabadell Spain
1 shared publication Albert Sueiras-Gil
Department of Surgery, Viladecans Hospital, Barcelona, Spain
1 shared publicationAlejandra Prieto-Gundin
Department of Pediatric Anesthesiology, Sant Joan de Déu Hospital, Barcelona Children's Hospital, Barcelona, Spain
1 shared publication- Alejandro Solís-Peña
Colorectal Surgery, Department of General and Digestive Surgery, Vall d’Hebron University Hospital, Barcelona, Spain
1 shared publication - Alexander Almendral
VINCat Program Catalonia Spain
1 shared publication
Latest Publications
- 15 July 2025
- Published by Elsevier in Biomedical Signal Processing and Control
- Vol. 110
Simultaneous pharmacometric control optimization for advanced integrated multi-drug target infusions
- 15 July 2025
- Published by Elsevier in Biomedical Signal Processing and Control
- Vol. 110
Simultaneous pharmacometric control optimization for advanced integrated multi-drug target infusions
- Open Access
Multi-drug interaction target-controlled infusion from simultaneous optimization of pharmacometric models
Background Accurately controlling drug delivery is crucial for safe anesthesia. Target-controlled infusion (TCI) systems use pharmacokinetic and pharmacodynamic (PK/PD) models to administer intravenous agents to reach target concentrations. However, TCI’s operation is restricted to a single-drug and a linear PK/PD model, not accounting for drug interactions. Dose-response interaction (DRI) models quantify such interactions by representing shared effects as a function of agents’ concentrations. For example, the co-administration of an analgesic and a hypnotic with TCI leads to an uncontrolled synergy. Methods We introduce a new administering methodology for multi-drug infusions, interaction target-controlled infusion (iTCI), that combines the PK/PD models of the co-administered drugs and their interactions into a single optimal non-linear dynamic control problem with terminal constraints. Results Incorporating DRI and PK/PD models allows novel administration procedures. Simulations of iTCI in different clinical scenarios under propofol and remifentanil co-administrations are presented. These show that: (1) iTCI requires lower administered volumes than TCI to reach simultaneously the same target concentrations. (2) It offers optimal interdependent administrations that address not only concentration targets but also effect targets. (3) iTCI comes with additional constraints on the administration, including controlled titrations along iso-effect conditions (isoboles) or (5) directly limiting plasma concentration levels. (6) Unlike TCI, iTCI can include different exerted effects (ke0) per drug, particularly relevant for opioids. Conclusion The iTCI is a versatile multi-drug infusion paradigm where effects and interactions play a relevant role - providing better delivery profiles than current TCI while opening the door for using non-linear PK/PD descriptions in anesthesia.
Open AccessMulti-drug interaction target-controlled infusion from simultaneous optimization of pharmacometric models
Background Accurately controlling drug delivery is crucial for safe anesthesia. Target-controlled infusion (TCI) systems use pharmacokinetic and pharmacodynamic (PK/PD) models to administer intravenous agents to reach target concentrations. However, TCI’s operation is restricted to a single-drug and a linear PK/PD model, not accounting for drug interactions. Dose-response interaction (DRI) models quantify such interactions by representing shared effects as a function of agents’ concentrations. For example, the co-administration of an analgesic and a hypnotic with TCI leads to an uncontrolled synergy. Methods We introduce a new administering methodology for multi-drug infusions, interaction target-controlled infusion (iTCI), that combines the PK/PD models of the co-administered drugs and their interactions into a single optimal non-linear dynamic control problem with terminal constraints. Results Incorporating DRI and PK/PD models allows novel administration procedures. Simulations of iTCI in different clinical scenarios under propofol and remifentanil co-administrations are presented. These show that: (1) iTCI requires lower administered volumes than TCI to reach simultaneously the same target concentrations. (2) It offers optimal interdependent administrations that address not only concentration targets but also effect targets. (3) iTCI comes with additional constraints on the administration, including controlled titrations along iso-effect conditions (isoboles) or (5) directly limiting plasma concentration levels. (6) Unlike TCI, iTCI can include different exerted effects (ke0) per drug, particularly relevant for opioids. Conclusion The iTCI is a versatile multi-drug infusion paradigm where effects and interactions play a relevant role - providing better delivery profiles than current TCI while opening the door for using non-linear PK/PD descriptions in anesthesia.
- Open Access
- 14 March 2023
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 109 (4) , 737-751
Leveraging a nationwide infection surveillance program to implement a colorectal surgical site infection reduction bundle: a pragmatic, prospective, and multicenter cohort study
Background: Bundled interventions usually reduce surgical site infection (SSI) when implemented at single hospitals, but the feasibility of their implementation at the nationwide level and their clinical results are not well established. Materials and Methods: Pragmatic interventional study to analyze the implementation and outcomes of a colorectal surgery care bundle within a nationwide quality improvement program. The bundle consisted of antibiotic prophylaxis, oral antibiotic prophylaxis (OAP), mechanical bowel preparation, laparoscopy, normothermia, and a wound retractor. Control group (CG) and Intervention group (IG) were compared. Overall SSI, superficial (S-SSI), deep (D-SSI), and organ/space (O/S-SSI) rates were analyzed. Secondary endpoints included microbiology, 30-day mortality, and length of hospital stay. Results: A total of 37 849 procedures were included, 19 655 in the CG and 18 194 in the IG. In all, 5462 SSIs (14.43%) were detected: 1767 S-SSI (4.67%), 847 D-SSI (2.24%), and 2838 O/S-SSI (7.5%). Overall SSI fell from 18.38% (CG) to 10.17% (IG), odds ratio (OR) of 0.503 [0.473–0.524]. O/S-SSI rates were 9.15% (CG) and 5.72% (IG), OR of 0.602 [0.556–0.652]. The overall SSI rate was 16.71% when no measure was applied and 6.23% when all six were used. Bundle implementation reduced the probability of overall SSI (OR: 0.331; CI95: 0.242–0.453), and also O/S-SSI rate (OR: 0.643; CI95: 0.416–0.919). In the univariate analysis, all measures except normothermia were associated with a reduction in overall SSI, while only laparoscopy, OAP, and mechanical bowel preparation were related to a decrease in O/S-SSI. Laparoscopy, wound retractor, and OAP decreased overall SSI and O/S-SSI in the multivariate analysis. Conclusions: In this cohort study, the application of a specific care bundle within a nationwide nosocomial infection surveillance system proved feasible and resulted in a significant reduction in overall and O/S-SSI rates in the elective colon and rectal surgery. The OR for SSI fell between 1.5 and 3 times after the implementation of the bundle.
- 14 March 2023
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 109 (4) , 737-751
Open AccessLeveraging a nationwide infection surveillance program to implement a colorectal surgical site infection reduction bundle: a pragmatic, prospective, and multicenter cohort study
Background: Bundled interventions usually reduce surgical site infection (SSI) when implemented at single hospitals, but the feasibility of their implementation at the nationwide level and their clinical results are not well established. Materials and Methods: Pragmatic interventional study to analyze the implementation and outcomes of a colorectal surgery care bundle within a nationwide quality improvement program. The bundle consisted of antibiotic prophylaxis, oral antibiotic prophylaxis (OAP), mechanical bowel preparation, laparoscopy, normothermia, and a wound retractor. Control group (CG) and Intervention group (IG) were compared. Overall SSI, superficial (S-SSI), deep (D-SSI), and organ/space (O/S-SSI) rates were analyzed. Secondary endpoints included microbiology, 30-day mortality, and length of hospital stay. Results: A total of 37 849 procedures were included, 19 655 in the CG and 18 194 in the IG. In all, 5462 SSIs (14.43%) were detected: 1767 S-SSI (4.67%), 847 D-SSI (2.24%), and 2838 O/S-SSI (7.5%). Overall SSI fell from 18.38% (CG) to 10.17% (IG), odds ratio (OR) of 0.503 [0.473–0.524]. O/S-SSI rates were 9.15% (CG) and 5.72% (IG), OR of 0.602 [0.556–0.652]. The overall SSI rate was 16.71% when no measure was applied and 6.23% when all six were used. Bundle implementation reduced the probability of overall SSI (OR: 0.331; CI95: 0.242–0.453), and also O/S-SSI rate (OR: 0.643; CI95: 0.416–0.919). In the univariate analysis, all measures except normothermia were associated with a reduction in overall SSI, while only laparoscopy, OAP, and mechanical bowel preparation were related to a decrease in O/S-SSI. Laparoscopy, wound retractor, and OAP decreased overall SSI and O/S-SSI in the multivariate analysis. Conclusions: In this cohort study, the application of a specific care bundle within a nationwide nosocomial infection surveillance system proved feasible and resulted in a significant reduction in overall and O/S-SSI rates in the elective colon and rectal surgery. The OR for SSI fell between 1.5 and 3 times after the implementation of the bundle.
- 4 October 2022
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 129 (6) , 868-878
Remifentanil pharmacodynamics during conscious sedation using algometry: a more clinically relevant pharmacodynamical model
- 4 October 2022
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 129 (6) , 868-878
Remifentanil pharmacodynamics during conscious sedation using algometry: a more clinically relevant pharmacodynamical model
- 1 February 2019
- Published by Edizioni Minerva Medica in Minerva Anestesiologica
- Vol. 85 (2) , 173-188
Brugada Syndrome: anesthetic considerations and management algorithm
Brugada Syndrome is characterized by arrhythmogenic risk that may be exacerbated by different metabolic and pharmacological factors. Since its first description, knowledge of this syndrome and its detection by physicians belonging to different specialties have gradually increased. The risk of arrhythmias is well known to increase in the postoperative period, and this risk is particularly accentuated in patients with Brugada Syndrome. The purpose of this review is to analyze the relationship between this syndrome and anesthesia; establish recommendations for the safe management of these patients in the surgical setting; and update the relevant concepts regarding the safety of drug administration in individuals with Brugada Syndrome.
- 1 February 2019
- Published by Edizioni Minerva Medica in Minerva Anestesiologica
- Vol. 85 (2) , 173-188
Brugada Syndrome: anesthetic considerations and management algorithm
Brugada Syndrome is characterized by arrhythmogenic risk that may be exacerbated by different metabolic and pharmacological factors. Since its first description, knowledge of this syndrome and its detection by physicians belonging to different specialties have gradually increased. The risk of arrhythmias is well known to increase in the postoperative period, and this risk is particularly accentuated in patients with Brugada Syndrome. The purpose of this review is to analyze the relationship between this syndrome and anesthesia; establish recommendations for the safe management of these patients in the surgical setting; and update the relevant concepts regarding the safety of drug administration in individuals with Brugada Syndrome.
- Open Access
- 6 June 2018
- Published by Asociacion Anestesia Reannimacion Espana, AnestesiaR in Revista Electrónica Anestesiar
- Vol. 10 (5) , 3
Actualización 2017 Guías prácticas para el ayuno preoperatorio. ¿Alguna novedad?
Actualización 2017 de las "Guías Prácticas de Ayuno Preoperatorio y el Uso de Agentes Farmacológicos para reducir el riesgo de aspiración pulmonar publicado por la ASA (American Society of Anesthesiologists) en 2011.
- 6 June 2018
- Published by Asociacion Anestesia Reannimacion Espana, AnestesiaR in Revista Electrónica Anestesiar
- Vol. 10 (5) , 3
Open AccessActualización 2017 Guías prácticas para el ayuno preoperatorio. ¿Alguna novedad?
Actualización 2017 de las "Guías Prácticas de Ayuno Preoperatorio y el Uso de Agentes Farmacológicos para reducir el riesgo de aspiración pulmonar publicado por la ASA (American Society of Anesthesiologists) en 2011.
- Open Access
- 31 March 2018
- Published by Asociacion Anestesia Reannimacion Espana, AnestesiaR in Revista Electrónica Anestesiar
- Vol. 10 (3) , 6
¿Es útil la dexametasona en Anestesia? Actualización 2017.
La dexametasona se utiliza con frecuencia en el contexto perioperatorio, incluyendo la profilaxis contra las náuseas y los vómitos postoperatorios, la reducción de la presión en las vías respiratorias, en el edema cerebral, y también puede ser útil en el tratamiento del dolor agudo y crónico. Es un glucocorticoide sintético, de mínima actividad mineralocorticoide y con acciones que se asemejan a las de las hormonas esteroides. Actúa como antiinflamatorio e inmunosupresor. Su potencia como fármaco antiinflamatorio es 25-50 veces la de la hidrocortisona y hasta 16 veces la de la prednisolona.
- 31 March 2018
- Published by Asociacion Anestesia Reannimacion Espana, AnestesiaR in Revista Electrónica Anestesiar
- Vol. 10 (3) , 6
Open Access¿Es útil la dexametasona en Anestesia? Actualización 2017.
La dexametasona se utiliza con frecuencia en el contexto perioperatorio, incluyendo la profilaxis contra las náuseas y los vómitos postoperatorios, la reducción de la presión en las vías respiratorias, en el edema cerebral, y también puede ser útil en el tratamiento del dolor agudo y crónico. Es un glucocorticoide sintético, de mínima actividad mineralocorticoide y con acciones que se asemejan a las de las hormonas esteroides. Actúa como antiinflamatorio e inmunosupresor. Su potencia como fármaco antiinflamatorio es 25-50 veces la de la hidrocortisona y hasta 16 veces la de la prednisolona.
- 1 February 2017
- Published by Elsevier in Journal of Clinical Anesthesia
- Vol. 36, 94-97
Monitoring of the intraoperative analgesia by pupillometry during laparoscopic splenectomy for splenic hydatid cyst
- 1 February 2017
- Published by Elsevier in Journal of Clinical Anesthesia
- Vol. 36, 94-97
Monitoring of the intraoperative analgesia by pupillometry during laparoscopic splenectomy for splenic hydatid cyst
- Open Access
- 1 January 1970
- Published by Asociacion Anestesia Reannimacion Espana, AnestesiaR in Revista Electrónica Anestesiar
- Vol. 10 (4) , 1
Ketamina y su indicación en el dolor agudo postoperatorio
La ketamina fue sintetizada por primera vez en 1962 por Calvin Stevens en Parke-Davis Co como anestésico alternativo a la fenciclidina. Se utilizó por primera vez en humanos en 1965 por Corssen y Domino bajo el nombre de "Ketalar". Se trataba de 20 presidiarios que se ofrecieron como voluntarios. En 1970 se introdujo en la clínica hospitalaria y poco después se administró ampliamente a los soldados americanos durante la guerra del Vietnam. Se describió como una "droga única" por ser capaz de producir hipnosis, analgesia y amnesia. Ningún otro fármaco utilizado en la práctica clínica produce estos tres efectos importantes al mismo tiempo.
- 1 January 1970
- Published by Asociacion Anestesia Reannimacion Espana, AnestesiaR in Revista Electrónica Anestesiar
- Vol. 10 (4) , 1
Open AccessKetamina y su indicación en el dolor agudo postoperatorio
La ketamina fue sintetizada por primera vez en 1962 por Calvin Stevens en Parke-Davis Co como anestésico alternativo a la fenciclidina. Se utilizó por primera vez en humanos en 1965 por Corssen y Domino bajo el nombre de "Ketalar". Se trataba de 20 presidiarios que se ofrecieron como voluntarios. En 1970 se introdujo en la clínica hospitalaria y poco después se administró ampliamente a los soldados americanos durante la guerra del Vietnam. Se describió como una "droga única" por ser capaz de producir hipnosis, analgesia y amnesia. Ningún otro fármaco utilizado en la práctica clínica produce estos tres efectos importantes al mismo tiempo.